REGN Regeneron Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Regeneron Pharmaceuticals is trading 13.7% down today in a sharp reversal following a recent rally
Regeneron Pharmaceuticals is trading 13.7% down at $655.22 in after-hours trading, marking a sharp reversal from its strong performance throughout late July...
🟢 Regeneron Pharmaceuticals is trading 4% up today after Q2 earnings beat and upgraded margin outlook
Regeneron Pharmaceuticals is trading at $723.48 (+4.03%) after reporting second-quarter results that beat Wall Street estimates and raising its full-year...
🟢 Regeneron Pharmaceuticals is trading 5.4% up today after a strong Q2 earnings beat
Regeneron Pharmaceuticals is trading 5.4% up at $733.00 after reporting second-quarter financial results that significantly exceeded analyst expectations. •...
Regeneron Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Regeneron Pharmaceuticals is expected to report Q2 2026 revenue of $3.82 billion and EPS of $8.00, while the current stock price of $695.18 remains...
🟢 Regeneron Pharmaceuticals is trading 4.2% up today, outperforming a weak biotech sector
Regeneron Pharmaceuticals is trading 4.2% up at $695.14 today, outperforming both the broader market and its biotech peers despite a lack of company-specific...
Regeneron Sued After $11 Billion Market Loss, Alleged Flawed Melanoma Trial Data
Regeneron Pharmaceuticals faces a securities class action lawsuit regarding its Phase 3 melanoma trial for Fianlimab and Libtayo. The lawsuit alleges the...
🟢 Regeneron Pharmaceuticals is trading 8.2% up today amid U.S. healthcare and tariff policy headlines
Regeneron Pharmaceuticals is trading 8.2% higher at $705.46 today amid active interest in the biotech and pharmaceutical sectors following U.S. healthcare and...
🟢 REGN is trading 4.1% up today as Benchmark upgrades to Buy on pipeline strength
REGN is trading 4.1% up at $676.58 as investors respond to a fresh analyst upgrade and look past a one-time Q2 IPR&D charge to the long-term pipeline story. •...
Regeneron's first quarter 2026 revenue grew 19% to $3.6B, beating estimates on strong Dupixent performance.
Regeneron reported first quarter 2026 revenues of $3.61 billion, up 19% year-over-year, and non-GAAP diluted EPS of $9.47. The results significantly exceeded...
Regeneron Pharmaceuticals Inc Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
Regeneron is expected to report Q1 2026 revenue of $3.41 billion and a consensus EPS of $8.36, with the current stock price of $751.57 trading below the...